Downregulation of the expression of mCRPs CD46, CD55, and CD59 improved the efficacy of rituximab and the anti-CD20 mAb ofatumumab in lymphoma and leukemia cell lines and primary CLL samples [6, 25]. This evidence concerns the gene CD46 and lymphoma.